| Q51569742 | A cholecystokinin-B receptor antagonist potentiates GABAergic and glycinergic inhibition in the nucleus of the solitary tract of the rat. |
| Q35753229 | Acid-base dysregulation and chemosensory mechanisms in panic disorder: a translational update |
| Q36494862 | Alterations in activity and energy expenditure contribute to lean phenotype in Fischer 344 rats lacking the cholecystokinin-1 receptor gene |
| Q48511467 | Alterations in brain cholecystokinin receptors in suicide victims |
| Q77354200 | An association of NAG levels and a mutation of the CCK gene in panic disorder patients |
| Q36783145 | Ancient Anxiety Pathways Influence Drosophila Defense Behaviors |
| Q41973984 | Antidepressant-like effects of CCKB antagonists in mice: antagonism by naltrindole |
| Q35236487 | Are there anxious genes? |
| Q43678376 | Arginine-vasopressin and oxytocin response to cholecystokinin-tetrapeptide. |
| Q47702259 | Association of cholecystokinin-A receptor gene polymorphisms and panic disorder in Japanese |
| Q43861876 | Association studies of the CT repeat polymorphism in the 5' upstream region of the cholecystokinin B receptor gene with panic disorder and schizophrenia in Japanese subjects |
| Q48869486 | Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats |
| Q51503680 | Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of Magnolia bark, evaluated by an elevated plus-maze test in mice. |
| Q42175984 | Benzodiazepine/cholecystokinin interactions at functional CCK receptors in rat brain |
| Q37686937 | Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition |
| Q38881060 | Brain Circulation during Panic Attack: A Transcranial Doppler Study with Clomipramine Challenge |
| Q28243274 | CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies |
| Q51093650 | CCK in anxiety and cognitive processes. |
| Q40753318 | CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons |
| Q28137628 | CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology |
| Q93919854 | CCK4-induced panic in healthy subjects II: neurochemical correlates |
| Q36236103 | Cholecystokinin and adrenal-cortex secretion |
| Q87473348 | Cholecystokinin and panic disorder |
| Q34060773 | Cholecystokinin and panic disorder--three unsettled questions |
| Q47737537 | Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy |
| Q36071597 | Cholecystokinin antagonists--a toxicologic perspective |
| Q41294359 | Cholecystokinin in anxiety |
| Q33486647 | Cholecystokinin peptides in cerebrospinal fluid: a study in healthy male subjects. |
| Q30532041 | Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models. |
| Q42716106 | Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens |
| Q48657997 | Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia |
| Q34464184 | Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations |
| Q36962703 | Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour? |
| Q34420892 | Cholecystokinin: a multi-functional molecular switch of neuronal circuits |
| Q43658284 | Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in healthy volunteers |
| Q52185367 | Decrease in short-term memory function induced by CCK-4 in healthy volunteers. |
| Q81247560 | Determination of peptide hormones of brain and intestine by CE with ESI-MS detection |
| Q73671011 | Development of a sensitive and specific assay system for cholecystokinin tetrapeptide |
| Q46423269 | Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone |
| Q33920881 | Dose ranging study of the effects of cholecystokinin in healthy volunteers |
| Q48632311 | Effect of central and peripheral administrations of cholecystokinin-tetrapeptide on panic-like reactions induced by stimulation of the dorsal periaqueductal grey area in the rat. |
| Q44407150 | Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study |
| Q33921982 | Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder |
| Q72483615 | Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers |
| Q43668186 | Effects of forebrain microinjection of cholecystokinin on dopamine cell firing rate |
| Q33862569 | Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder |
| Q28083141 | Emerging drugs for the treatment of anxiety |
| Q73134844 | Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers |
| Q44337191 | Emotional perception modulated by an opioid and a cholecystokinin agonist |
| Q31813598 | Enhanced cortical extracellular levels of cholecystokinin-like material in a model of anticipation of social defeat in the rat. |
| Q51115170 | Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice. |
| Q33275210 | Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study |
| Q43801694 | Evaluation of the effects of PD 134308 (CI-988), A CCK-B antagonist, on the punished responding of squirrel monkeys |
| Q37395948 | Evidence for an involvement of the brain cholecystokinin B receptor in anxiety |
| Q35686873 | Experimental panic provocation in healthy man-a translational role in anti-panic drug development? |
| Q44593095 | Experimental provocation of panic attacks as a human experimental model for anxiety |
| Q40445872 | Exploring the association between a cholecystokinin promoter polymorphism (rs1799923) and posttraumatic stress disorder in combat veterans |
| Q51121767 | Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. |
| Q52719732 | Flushing Disorders Associated with Gastrointestinal Symptoms: Part 2, Systemic Miscellaneous Conditions. |
| Q33311506 | Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers |
| Q36873248 | Functional neuroimaging studies in posttraumatic stress disorder |
| Q34730748 | Generalised anxiety disorder: treatment options |
| Q30473426 | Human models as tools in the development of psychotropic drugs |
| Q51115263 | Human pharmacokinetics and tolerability of L-365,260, a novel cholecystokinin-B antagonist. |
| Q44268119 | Hypothalamic-pituitary adrenal response to cholecystokinin-B receptor agonism is resistant to cortisol feedback inhibition |
| Q48354695 | Identification of a compound short tandem repeat stretch in the 5'-upstream region of the cholecystokinin gene, and its association with panic disorder but not with schizophrenia |
| Q30397401 | Identification of neuropeptide receptors expressed by melanin-concentrating hormone neurons |
| Q42704380 | Impairment of stress adaptive behaviours in rats by the CCKA receptor antagonist, devazepide |
| Q41149388 | In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCKB agonist [3H]pBC 264 |
| Q42642363 | Increased anxiety behavior in OLETF rats without cholecystokinin-A receptor |
| Q48357559 | Inhibition by 5-HT3 receptor antagonists of release of cholecystokinin-like immunoreactivity from the frontal cortex of freely moving rats |
| Q40788390 | Interaction between neuropeptide Y and sigma ligands in the modulation of CRF and stress-induced alteration of gastrointestinal function |
| Q30392035 | Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention |
| Q57422547 | Intra- and inter-individual correlations between cholecystokinin and corticotropin-releasing hormone concentrations in human cerebrospinal fluid |
| Q36082387 | Irritable bowel syndrome. How to relieve symptoms enough to improve daily function |
| Q52206236 | Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. |
| Q46938208 | Megestrol attenuates the hormonal response to CCK-4-induced panic attacks |
| Q52211767 | Multiple, small doses of cholecystokinin octapeptide are more efficacious at inducing taste aversion conditioning than single, large doses |
| Q24535665 | Neurobiological investigations into the role of cholecystokinin in panic disorder |
| Q35686869 | Neurobiology of panic and pH chemosensation in the brain |
| Q41713087 | Neurobiology of panic disorder |
| Q33717424 | Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implications |
| Q35071526 | Neuroendocrine pharmacology of stress. |
| Q73855141 | Neurohormonal responses to cholecystokinin tetrapeptide: a comparison of younger and older healthy subjects |
| Q43832568 | Neuronal expression of Fos protein in the brain after intravenous injection of gastrin in rats |
| Q34272451 | Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin |
| Q30453815 | Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y. |
| Q30432423 | Neuropeptidergic signaling partitions arousal behaviors in zebrafish |
| Q38766099 | Neuropeptides and anxiety disorders |
| Q57150535 | No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder |
| Q48187400 | One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI. |
| Q60645802 | Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats |
| Q44631146 | PD-136,450: a CCK2 (gastrin) receptor antagonist with antisecretory, anxiolytic and antiulcer activity |
| Q41713042 | Panic disorder in the general medical setting |
| Q42552995 | Pentagastrin has panic-inducing properties in obsessive compulsive disorder |
| Q34318557 | Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients |
| Q48089410 | Pentagastrin infusions in patients with panic disorder II. Neuroendocrinology |
| Q48378821 | Pharmacological characterisation of cortical gamma-aminobutyric acid type A (GABAA) receptors in two Wistar rat lines selectively bred for high and low anxiety-related behaviour |
| Q24673072 | Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models |
| Q36860047 | Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs |
| Q46018094 | Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings. |
| Q74594100 | Possible association of a cholecystokinin promotor polymorphism (CCK-36CT) with panic disorder |
| Q37633608 | Prefrontal cortical circuit for depression- and anxiety-related behaviors mediated by cholecystokinin: role of ΔFosB. |
| Q37162538 | Qualitative Analysis of Emotions: Fear and Thrill |
| Q47972586 | Reduced anxious behavior in mice lacking the CCK2 receptor gene |
| Q48129563 | Regional brain activity during transient self-induced anxiety and anger in healthy adults |
| Q50536985 | Relationship between SCL-90, Maudsley Personality Inventory and CCK4-induced intracellular calcium response in T cells. |
| Q78125315 | Role of cholecystokinin type B receptors in ultrasound induced behavior in rats |
| Q51102687 | Role of different neurotransmitter systems in the cholecystokinin octapeptide-induced anxiogenic response in rats. |
| Q36156471 | Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder |
| Q48431716 | Sulfated cholecystokinin (26-33) induces mild taste aversion conditioning in rats when administered by three different routes |
| Q34550349 | The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist |
| Q48824499 | The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze |
| Q40753314 | The cholecystokinin hypothesis of anxiety and panic disorder |
| Q37980110 | The cholecystokinin hypothesis of panic and anxiety disorders: a review |
| Q34420283 | The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients |
| Q51101715 | The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. |
| Q34200077 | The genetics of panic disorder |
| Q87473343 | The genetics of panic disorder: state of the art |
| Q34241282 | The psychobiology of anxiolytic drugs. Part 1: Basic neurobiology |
| Q41061878 | Two faces of cholecystokinin: anxiety and schizophrenia |
| Q48708390 | Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion |
| Q44061649 | rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest |